A Study of Prognostic Values of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia Patients With Allo-HSCT
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 500
- 试验地点
- 1
- 主要终点
- 1-year relapse rate after allo-HSCT
研究概览
简要总结
Acute myeloid leukemia (AML) is a genetically heterogeneous disease and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment option for AML except for AML-M3. Relapse remains the major cause of treatment failure after allo-HSCT. Molecular residual disease has been shown to be a strong risk factor for relapse after HSCT. In this study, the investigators will detect mutations before/after allo-HSCT by using next-generation sequencing (NGS) technique to measure residual disease and evaluate the prognostic impact of molecular residual disease in a cohort of AML participants receiving allo-HSCT.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years or old;
- •Clinical diagnosis of acute myeloid leukemia (AML);
- •Availabe records of MICM and NGS results at diagnosis;
- •Be going to receive allo-HSCT.
排除标准
- •Active malignancy;
- •Pregnant or breast feeding women.
结局指标
主要结局
1-year relapse rate after allo-HSCT
时间窗: 1 year after allo-HSCT
1-year relapse rate after allo-HSCT
次要结局
- 1-year recurrence-free survival (RFS)(1 year after allo-HSCT)
- 1-year overall survival (OS)(1 year after allo-HSCT)
研究者
Wu Depei
professor
The First Affiliated Hospital of Soochow University